If approved, the co-administration of Arexvy and Shingrix could provide a more convenient vaccination regimen for patients ...

UK drugmaker GSK presented positive Phase III trial data at the European Geriatric Medicine Society Congress. The trial ...

Moderna has delayed its break-even goal by two years, pushing it to 2028, due to slower regulatory processes for key products ...

Derived from the Latin adjuvare (to help or aid), adjuvants enhance antigen-specific vaccine immunogenicity. Added only when ...

Find insight on GSK and more in the latest Market Talks covering the Health Care sector.

The vaccine maker last month projected sales of $3 billion and $3.5 billion for this year, which will be its lowest annual ...

Analyst Graham Parry of Bank of America Securities maintained a Sell rating on GlaxoSmithKline (GSK – Research Report), retaining the ...

The updated COVID-19 vaccines are officially available at U.S. pharmacies across the country. Here are other vaccines recommended for adults.

Moderna pushed back its break-even goal by two years on Thursday as it delayed the timeline for developing several key ...

Moderna on Thursday said it expects sales of between $2.5 billion and $3.5 billion next year, and forecast that new product launches would drive an average annual growth rate of 25% in revenue between ...